Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Rare disease start-up Bio Blast Pharma completes $32.7mm US IPO

Executive Summary

Bio Blast Pharma Ltd., an Israeli start-up focused on rare and ultra-rare genetic diseases, completed its initial public offering in the US. The company netted $32.7mm through the sale of 3.2mm ordinary shares at $11. Bio Blast is the sixth Israeli firm to price a US IPO thus far in 2014, in addition to Lumenis, MediWound, Galmed, Vascular Biogenics, and Macrocure.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies

Advertisement
UsernamePublicRestriction

Register